FDA approves Gilead’s remdesivir as coronavirus treatment

A lab technicians shows the coronavirus disease (COVID-19) treatment drug “Remdesivir”.

Amr Abdallah Dalsh | Reuters

The Food and Drug Administration on Thursday approved Gilead Sciences‘ antiviral drug remdesivir as a treatment for the coronavirus.

In May, the FDA granted the drug an emergency use authorization, allowing hospitals and doctors to use the drug on patients hospitalized with the disease even though the drug has not been formally approved by the agency. The intravenous drug has helped shorten the recovery time of some hospitalized Covid-19 patients.

The drug will be used for Covid-19 patients requiring hospitalization, Gilead said. Remdesivir is now the first and only fully approved treatment in the U.S. for Covid-19, which has infected more than 41.3 million and killed more than 1 million, according to data compiled by Johns Hopkins University.

“Since the beginning of the COVID-19 pandemic, Gilead has worked relentlessly to help find solutions to this global health crisis,” Gilead CEO Daniel O’Day said in a statement. “It is incredible to be in the position today, less than one year since the earliest case reports of the disease now known as COVID-19, of having an FDA-approved treatment in the U.S. that is available for all appropriate patients in need.”

This is breaking news. Please check back for updates.

Products You May Like

Articles You May Like

IRS issues final regs on 1031 exchanges
Investors try to gauge if retail’s stay-at-home trends will stick as Covid vaccine is in sight
Stocks making the biggest moves midday: Tesla, Dollar Tree, Carnival, Best Buy and more
How to break the late rent, missed mortgage payment cycle
HP jumps on earnings beat and rising PC notebook sales

Leave a Reply

Your email address will not be published. Required fields are marked *